You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國醫療集團(08225.HK)將負責利托那韋口服液上市前後臨床研究推廣和治療
阿思達克 02-17 09:37

中國醫療集團(08225.HK)公布,邁可欣(利托那韋口服液)複產註冊於今年2月14日獲得批准(首家),利托那韋為抗病毒蛋白(酉每)抑制劑,且洛匹那韋/利托那韋為國家衛健委針對新型肺炎的國家版診療方案推薦用藥。

集團指,旗下新型冠狀病毒肺炎臨床特別專案研究組,中國科學院武漢病毒研究所等也發現邁可欣對新型冠狀病毒(COVID19)有抑制作用。集團將負責邁可欣的上市前後「臨床研究推廣和治療」。

同時,由集團組織的關於瑞德西韋 Remdesivir(RNA 聚合(酉每)抑制劑)新藥研究申報和拓展性同情用藥,也收到國家藥監局的再次積極回復和交流。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account